The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Targeting rare genomic subgroups with KRAS G12C inhibitors in solid tumors
Matthew Krebs, MD, PhD, University of Manchester, Manchester, UK, highlights the increasing importance of identifying rare subgroups of patients in solid tumors, particularly those with specific genomic alterations such as KRAS G12C mutations. KRAS G12C inhibitors such as divarasib may have potential benefit for these patients and collecting more data will be necessary to fully understand the benefits of these medicines. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, it’s not quite changed the landscape yet, but increasingly in oncology, we’re coming across rarer and rarer subgroups of patients. So it’s not just about the histological diagnosis of pancreatic or cholangiocarcinoma, but what’s the genomic alteration behind that that could be driving their tumour. So as we’ve started to see KRAS G12C alterations at pretty low frequency in these disease types, really low, so 1 to 2% of patients, if that...
Well, it’s not quite changed the landscape yet, but increasingly in oncology, we’re coming across rarer and rarer subgroups of patients. So it’s not just about the histological diagnosis of pancreatic or cholangiocarcinoma, but what’s the genomic alteration behind that that could be driving their tumour. So as we’ve started to see KRAS G12C alterations at pretty low frequency in these disease types, really low, so 1 to 2% of patients, if that. But in those scenarios, these patients could really stand to benefit from drugs like Sotorasib or other KRAS G12C inhibitors. And really, we’re just at the early stages of identifying the benefit of these medicines. But I think we need to collect more data. It looks very promising at the moment. And really, what we’re thinking about for the future is a sort of tumour agnostic indication. So for the rare instances, we find KRAS G12C mutations in other cancers outside of colon and lung. We might, in the future, have options for these patients who could really benefit from oral treatments that are well tolerated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
